Roche's Tecentriq Wins U.S. Approval for Aggressive Triple-Negative Breast Cancer
FDA approves Roche's Tecentriq for aggressive triple-negative breast cancer, though more evidence of benefit is required.
Roche won U.S. approval on Friday for its immunotherapy Tecentriq to treat a significant portion of patients with aggressive triple-negative breast cancer. The Swiss drugmaker still has additional work to do to prove the treatment's full merit. Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/3oK5Tmm87J4/roches-tecentriq-wins-u-s-approval-for-aggressive-breast-cancer-idUSKCN1QP20C
VITALIS: For people facing triple-negative breast cancer, this opens the door to a new treatment option that could help their bodies fight back more effectively. It shows how cancer care keeps evolving toward using the immune system in ways that matter for everyday patients.
Sources (1)
- [1]Roche's Tecentriq wins U.S. approval for aggressive breast cancer(http://feeds.reuters.com/~r/reuters/healthNews/~3/3oK5Tmm87J4/roches-tecentriq-wins-u-s-approval-for-aggressive-breast-cancer-idUSKCN1QP20C)